Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,373Revenue (TTM) $M130Net Margin (%)-178.1Altman Z-Score-3.8
Enterprise Value $M1,667EPS (TTM) $-1.2Operating Margin %-165.2Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.3Pre-tax Margin (%)-180.7Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio1.7Cash flow > EarningsY
Price/Sales10.45-y EBITDA Growth Rate %--Current Ratio1.7Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-42.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M191ROIC % (ttm)-203.1Gross Margin Increase y-yY

Gurus Latest Trades with ARIA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
ARIAMichael Price 2016-03-31 Add0.23%$4.48 - $6.66
$ 7.1828%Add 31.10%1,075,000
ARIAMichael Price 2015-12-31 Add0.08%$5.78 - $7.19
$ 7.189%Add 14.45%820,000
ARIAMichael Price 2015-09-30 Add0.15%$5.81 - $9.89
$ 7.18-7%Add 30.27%716,500
ARIAJoel Greenblatt 2015-06-30 Sold Out $7.9 - $9.71
$ 7.18-19%Sold Out0
ARIAMichael Price 2015-03-31 Buy 0.6%$6.1 - $8.97
$ 7.18-3%New holding550,000
ARIAJoel Greenblatt 2015-03-31 Buy $6.1 - $8.97
$ 7.18-3%New holding16,344
ARIAGeorge Soros 2014-12-31 Sold Out -0.01%$5.02 - $7.46
$ 7.1814%Sold Out0
ARIAGeorge Soros 2014-09-30 Reduce-0.04%$5.01 - $6.5
$ 7.1823%Reduce -85.00%150,000
ARIAGeorge Soros 2014-06-30 Add0.02%$6.3 - $8.52
$ 7.184%Add 100.00%1,000,000
ARIAGeorge Soros 2014-03-31 Reduce-0.08%$6.46 - $8.99
$ 7.18-7%Reduce -74.36%500,000
ARIAGeorge Soros 2013-12-31 Buy 0.11%$2.2 - $18.8
$ 7.1839%New holding1,950,000
ARIAGeorge Soros 2012-06-30 Sold Out -0.15%$14.6 - $17.82
$ 7.18-56%Sold Out0
ARIAGeorge Soros 2012-03-31 Buy 0.15%$12.73 - $16.32
$ 7.18-48%New holding635,000
ARIAGeorge Soros 2011-12-31 Sold Out -0.07%$8.03 - $12.5
$ 7.18-34%Sold Out0
ARIAGeorge Soros 2011-09-30 Buy 0.07%$7.63 - $13.34
$ 7.18-32%New holding496,847
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARIA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!

ARIA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-06-22Sell23,999$7.28-1.37view
LAVIDAS ATHANESEDirector 2016-06-15Sell76,250$8.21-12.55view
Radaelli MassimoDirector 2016-06-14Sell108,569$8.25-12.97view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-05-23Sell17,762$8.08-11.14view
Panayiotopoulos ParisPresident and CEO 2016-05-12Buy26,990$7.41-3.1view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-05-02Sell11,700$7.130.7view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-04-22Sell21,409$7.37-2.58view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-03-22Sell23,834$6.589.12view
BERSTEIN DAVID LSVP, Chief IP Counsel 2016-03-21Sell2,375$6.4710.97view
Bollag Daniel MSr. VP, Reg. Affairs & Quality 2016-03-21Sell4,000$6.4710.97view

Quarterly/Annual Reports about ARIA:

News about ARIA:

Articles On GuruFocus.com
Michael Price Invests in 11 Companies in First Quarter May 19 2015 
Sarah Ketterer of Causeway Capital's Answers to GuruFocus Q&A Apr 07 2014 
Weekly CEO Sells Highlight: U.S. Bancorp, Restoration Hardware Holdings Inc, Ariad Pharmaceuticals, Jul 20 2013 
Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
3 Biotech Stocks To Consider Buying Right Now Jan 10 2012 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 10 2009 
Weekly CEO Buys Highlight: Citigroup Inc, ARIAD Pharmaceuticals Inc, Bruker BioSciences Corp, Akamai Aug 08 2009 

More From Other Websites
ARIAD Announces Webcast of Its Annual Stockholders Meeting Jun 24 2016
Five companies that could buy Ariad this year for as much as $2.9B Jun 23 2016
ARIAD Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ARIA) : June 21, 2016 Jun 21 2016
ARIAD Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARIA-US : June... Jun 20 2016
ARIAD Completes Strategic Review and Announces Plans for Growth Jun 17 2016
Why Mosaic, Vale, and Three Other Stocks Are in the Spotlight Jun 17 2016
ARIAD Initiates Submission Of NDA For Brigatinib Ahead Of Plan Jun 17 2016
ARIAD Announces Distribution Agreements for Iclusig® in Latin America and the Middle East/North... Jun 17 2016
ARIAD Initiates Submission of New Drug Application for Brigatinib to the U.S. Food and Drug... Jun 17 2016
ARIAD (ARIA) Presents Long-Term Phase II Data on Iclusig Jun 14 2016
Ariad Reveals Ponatinib's Long-Term Safety And Efficacy Data From Stage 2 Clinical Study Jun 13 2016
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial Jun 13 2016
Ariad Pharmaceuticals, Inc. (ARIA) To Seek Regulatory Clearance For Brigatinib In 3Q Jun 08 2016
What Helped Incyte Report Growth in 1Q16? Jun 08 2016
Research Coverage Scans Stocks on the Biotechnology Industry for Today Jun 08 2016
ARIAD to Host Analyst & Investor Day in New York City Jun 08 2016
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 07 2016
ARIAD (ARIA) Presents Phase II Study Data on Cancer Drug Jun 07 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)